Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 498935, 10 pages
http://dx.doi.org/10.1155/2013/498935
Research Article

Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial

1Department of Preventive Medicine, College of Korean Medicine, Daejeon University, 62 Daehak-ro, Daejeon 300-716, Republic of Korea
2Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Seoul 130-701, Republic of Korea
3Center for Clinical Research & Drug Development, Kyung Hee University, 1 Hoegi-dong, Seoul 130-701, Republic of Korea
4Family Medicine & Integrative Medicine, Seoul St. Mary’s Hospital, Catholic University Medical Center, Seoul 137-701, Republic of Korea
5Department of Internal Medicine, College of Korean Medicine, Semyung University, Bongbang-dong, Chungju 380-960, Republic of Korea
6Department of Korean Rehabilitation Medicine, College of Korean Medicine, Gachon University, Seongnam 461-701, Republic of Korea

Received 4 April 2013; Accepted 5 July 2013

Academic Editor: Chang Shik Yin

Copyright © 2013 Sunju Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. The purpose of this study was to assess the efficacy and safety of Taeeumjowi-tang (TJ001) as well as to estimate obesity-related factors. Methods. This was a 12-week trial with 5 visits. A total of 102 participants of both genders were randomized to either TJ001 ( ) group or the placebo group ( ). Subjects were administered 7 g of either TJ001 or placebo 3 times a day. The primary outcome was a rate of subjects who lost 5% or more of initial weight. Secondary outcomes included anthropometric parameters, lipid profiles, and body fat composition. Results. The subject response rate of ≥5% weight loss compared to baseline was similar in both groups, and no statistically significant difference was observed ( ). Changes in anthropometric parameters were greater during the first 4 weeks in the treatment group ( ). There were no significant changes in both within groups and between groups for lipid profile and body fat composition. No adverse event was reported in either group. Conclusion. Although the difference between the groups regarding a rate of subjects who lost 5% or more of initial weight did not show statistical significance, TJ001 appears to be beneficial in safely controlling weight.